SCYX News and Press, SCYNEXIS Inc. From 11/01/22

JERSEY CITY, N.J., Nov. 01, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced it will host a conference call and live webcast at 8:30 ...

Summary Scynexis launched a product for VVC where there is no significant commercial demand. An additional indication in preventing VVC is not likely to significantly increase sales. Commercial sales have been extraordinarily low and the company is responding by stopping comme...

SCYNEXIS ( NASDAQ: SCYX ) has announced that Ivor Macleod, an accomplished biopharma industry executive, has joined the Company as CFO. Mr. Macleod joined SCYNEXIS from Athersys, where he served as CFO since Jan. of 2020; previously he served as the CFO and CCO of Eis...

JERSEY CITY, N.J., Oct. 25, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that Ivor Macleod, an accomplished biopharma industry ex...

Cumulative interim analysis of outcomes by fungal disease type highlighted in a platform presentation demonstrates 82.3% positive clinical outcomes in patients treated with ibrexafungerp. All-cause mortality analysis shows 94.6% survival 30 days post-therapy in patients with invas...

SCYNEXIS, Inc. ( NASDAQ: SCYX ), a biotech focused on fungal infections, fell in the pre-market trading Thursday after announcing changes to its leadership team and the operational activities that include a workforce reduction. The Jersey City, New Jersey-based company said ...

SCYNEXIS is announcing a new strategic direction to refocus its resources on the clinical development of ibrexafungerp for severe, hospital-based indications in which higher long-term returns are expected, given the promising data generated to date in refractory fungal infections, includi...

JERSEY CITY, N.J., Oct. 11, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that interim data from the Phase 3 FURI study of oral ibrexaf...

JERSEY CITY, N.J., Sept. 09, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that Marco Taglietti, President and Chief Executive Off...

Approximately 83% of FURI patients with refractory Candida infections had positive clinical outcomes, defined as complete/partial response (56%) or no disease progression (27%). Data from the ongoing Phase 3 CARES study will also be presented demonstrating positive outcomes of...